Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial
- Citation:
- Ann Oncol vol 28 (9) 2225-2232
- Meeting Instance:
- SABCS 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2920
- Pharmas:
- Grants:
- U10CA180821
- Corr. Author:
- Authors:
- Gini F Fleming Prudence A Francis István Láng Eva M Ciruelos Meritxell Bellet Hervé R Bonnefoi Miguel A Climent Lorenzo Pavesi Harold J Burstein Silvana Martino Nancy E Davidson Charles E Geyer Jr Barbara A Walley Robert E Coleman Pierre Kerbrat Stefan Buchholz James N Ingle Manuela Rabaglio-Poretti Marco Colleoni Meredith M Regan
- Networks:
- LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-PA015, OH070
- Study
- IBCSG-24-02 (SOFT-TEXT)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- GnRH-agonist, adjuvant therapy, hormone receptor-positive, ovarian function suppression, premenopausal, triptorelin